Clinical Trials Sponsored by Cancer Insight, LLC

Total 1321 results

American Cancer Society, Inc.
Will2Love, LLC

Completed

The Find Your PATHS (Pragmatic Assessment of a Tool to Help Survivors) to Sexual Health and Parenthood Study (PATHS)

Fertility | Sexuality | Cancer-related Problem/Condition

United States
MedImmune LLC
National Cancer Institute (NCI)

Completed

CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

United States, Canada
Dana-Farber Cancer Institute
Pharmacyclics LLC.

Completed

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Waldenstrom's Macroglobulinemia

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Portland VA Medical Center

Completed

Exercise Program Among Lung Cancer Dyads (PEP-LC)

Depression | Quality of Life | Pain | Physical Activity | Lung Cancer | Lung Cancer Symptoms

United States
Sight Diagnostics
Tel Aviv Medical Center

Unknown

Performance Evaluation Study

Hematology
Rabin Medical Center
Night Sense Ltd

Completed

Development and Assessment of Feasibility of Non-invasive Multiple Sensor Hypo-Sense as a Tool for Detection of Hypoglycemia (Hypo-Sense)

Type 1 Diabetes | Nocturnal Hypoglycemia

Israel
OHSU Knight Cancer Institute
National Cancer Institute (NCI); GlaxoSmithKline; Millennium Pharmaceuticals,...

Terminated

Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma

United States
Abramson Cancer Center at Penn Medicine
Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Highlight Therapeutics

Terminated

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

Advanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Refractory Hepatocellular Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pharmacyclics LLC.

Completed

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Carcinoid Tumors | Pancreatic NET

United States
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center
Ortho-McNeil Janssen Scientific Affairs, LLC

Terminated

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

Breast Cancer | Fatigue | Gastrointestinal Cancer

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Not yet recruiting

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

United States
Abramson Cancer Center at Penn Medicine
Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma (MCC)

Merkel Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Pharmacyclics LLC.; Janssen Biotech, Inc.

Recruiting

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Celgene Corporation

Completed

Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Leukemia

United States
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

Lymphoma | Small Intestine Cancer

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Sezary Syndrome | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | T-Cell Prolymphocytic Leukemia | B-Cell Prolymphocytic Leukemia

United States
University of Michigan Rogel Cancer Center
Janssen Scientific Affairs, LLC

Recruiting

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (ASCLEPIuS)

Prostate Cancer

United States
University of Michigan Rogel Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Amgen

Active, not recruiting

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Sarcoma | Epithelioid Sarcoma | Cutaneous Angiosarcoma

United States
Jennifer Woyach
Pharmacyclics LLC.

Active, not recruiting

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
MedImmune LLC

Completed

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

Myeloma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Recruiting

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

Pancreatic Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Recruiting

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

Skin Carcinoma | Cutaneous Melanoma | Melanocytic Nevus

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms

Malignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm | Malignant Thoracic Neoplasm | Malignant Head and Neck Neoplasm | Malignant Breast Neoplasm

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Available

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

Malignant Neoplasm | Hematopoietic Cell Transplantation Recipient | Benign Neoplasm | Bone Marrow Transplantation Recipient

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Withdrawn

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

A Digital Intervention Protocol to Enhance Recovery After Head and Neck Surgery

Head and Neck Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer

Melanoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Active, not recruiting

Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors

Malignant Glioma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

Glioblastoma

United States
Oregon Health and Science University
OHSU Knight Cancer Institute

Withdrawn

Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)

COVID-19 | SARS-CoV-2

United States
OHSU Knight Cancer Institute
National Institutes of Health (NIH)

Completed

CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening

Cervical Cancer | Breast Cancer | Colorectal Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Medical Research Foundation, Oregon

Terminated

Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer

Prostate Carcinoma | Health Status Unknown

United States
Center For Sight
Science in Vision

Completed

Symfony/Synergy IOL Combination Outcomes

Presbyopia | Bilateral Cataract

United States
Center For Sight
Science in Vision

Completed

Synergy Lens Outcomes Evaluation

Presbyopia | Pseudophakia

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC; Janssen Scientific Affairs, LLC

Terminated

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC; Janssen Scientific Affairs, LLC

Completed

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

Colorectal Cancer | Colon Cancer | Colorectal Carcinoma | Colon Disease

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Enrolling by invitation

Pathogenesis of Hematologic Malignancies

Lymphoproliferative Disorders | Myelodysplastic Syndromes | Myeloproliferative Disorders | Acute Leukemia

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Terminated

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

Metastatic Malignant Neoplasm in the Brain | Primary Brain Neoplasm

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Terminated

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Active, not recruiting

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Central Nervous System Lymphoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); United States Department of Defense

Completed

Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer

Prostate Cancer | Precancerous Condition

United States
OHSU Knight Cancer Institute
Novartis; Oregon Health and Science University

Not yet recruiting

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Not yet recruiting

EMBRACE: Exercising Together

Breast Carcinoma | Prostate Carcinoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Recruiting

Predicting the Impact of Treatment Toxicities on Health During Cancer (PATTERN)

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Recruiting

Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC (SMARTER CRC)

Colorectal Carcinoma

United States

Clinical Trials Sponsored by Cancer Insight, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations